General considerations for viral safety control of recombinant therapeutic biotechnological products during the CTA phase
| Just accepted | Online first | Issue | Totals | |
|---|---|---|---|---|
| HTML pages views | 0 | 0 | 18 | 18 |
| PDF downloads | 0 | 0 | 6 | 6 |
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.
|